TRANSITION AGREEMENTTransition Agreement • May 22nd, 2013 • Cardiome Pharma Corp • Pharmaceutical preparations
This Transition Agreement (the “Agreement”) is made and entered into as of April 25, 2013 (the “Effective Date”) by and between CARDIOME PHARMA CORP., a Canadian corporation with offices at 6190 Agronomy Rd., Suite 405, Vancouver, B.C., Canada, V6T 1Z3 ("Cardiome"), MERCK SHARP & DOHME (SWITZERLAND) GMBH, a company organized under the laws of Switzerland with offices at Rue de Lausanne 27, Sion, 1950, Switzerland (“MSD Switzerland”) and MERCK SHARP & DOHME CORP. (as successor-in-interest to the entity formerly known as Merck & Co., Inc.), a corporation organized under the laws of New Jersey with offices at One Merck Drive, Whitehouse Station, NJ 08889-0100, U.S.A. (“MSD Corp.” and, together with MSD Switzerland, “Merck”). Cardiome, MSD Switzerland and MSD Corp. are each referred to from time to time herein either individually as a “Party” or collectively as the “Parties”.
